Imunon Inc
IMNN
Company Profile
Business description
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Contact
997 Lenox Drive
Suite 100
LawrencevilleNJ08648
USAT: +1 609 896-9100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.40 | 38.00 | -0.42% |
| CAC 40 | 8,241.24 | 85.01 | 1.04% |
| DAX 40 | 24,381.46 | 293.40 | 1.22% |
| Dow JONES (US) | 48,254.82 | 326.86 | 0.68% |
| FTSE 100 | 9,911.42 | 11.82 | 0.12% |
| HKSE | 26,922.73 | 226.32 | 0.85% |
| NASDAQ | 23,406.46 | 61.84 | -0.26% |
| Nikkei 225 | 51,063.31 | 220.38 | 0.43% |
| NZX 50 Index | 13,703.01 | 31.28 | 0.23% |
| S&P 500 | 6,850.92 | 4.31 | 0.06% |
| S&P/ASX 200 | 8,799.50 | 36.50 | -0.41% |
| SSE Composite Index | 4,000.14 | 2.62 | -0.07% |